$660M Biotech Co. Merger Offer Is Too Low, Investors Say
A shareholder in Osiris Therapeutics Inc. has filed a proposed class action in Maryland federal court challenging the terms of a planned $660 million merger with competitor Smith & Nephew PLC,...To view the full article, register now.
Already a subscriber? Click here to view full article